Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSH | P09668 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 3/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21266697 | 0.94 | CTSS (0.39) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL29097283 | 0.86 | AAK1 (0.33) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL25185691 | 0.86 | CTSK (0.41) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL30639521 | 0.86 | CTSK (0.41) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL66693 | 0.84 | CTSK (0.43) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL66694 | 0.84 | CTSK (0.43) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL29414284 | 0.84 | CTSK (0.44) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL19066777 | 0.83 | CTSK (0.39) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL25179484 | 0.83 | CTSK (0.39) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL25287502 | 0.81 | CTSK (0.44) | CTSKCTSSCTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484464-B1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3484464-B1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10442778-B2 | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10442778-B2 | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| EP-3484464-A1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190092738-A1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092738-A1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | US | disclosed |
| WO-2017165204-A1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165204-A1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092738-A1 | N1-PHENYLPROPANE-1,2-DIAMINE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN1A, TRPA1 | CTSK 1564/4885CTSS 2450/4885CTSL 3183/4885 |
| US-10442778-B2 | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN1A, TRPA1 | CTSK 1564/4885CTSS 2450/4885CTSL 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.